View PDF Version - RePub - Erasmus Universiteit Rotterdam

Chapter 4.2
204
References
1. Perrillo RP, Schiff ER, Davis GL et al. A randomized, con trolled trial of interferon alfa-2b alone
and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis
Interventional Therapy Group. N Engl J Med 1990; 323(5): 295–301.
2. Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alphainterferon
treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A
meta-analysis. Ann Intern Med 1993; 119(4): 312–323.
3. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination
treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46(4):
562–568.
4. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients
with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;
119(1): 172–180.
5. Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine.
Hepatology 2000; 32(4 Pt 1): 828–834.
6. van der Eijk AA, Niesters HG, Pas SD, de Man RA. Persist ence of YMDD variants after withdrawal
of lamivudine. J Hepatol 2002; 36(2): 304–305.
7. Stuyver LJ, Locarnini SA, Lok A et al. Nomenclature for antiviral-resistant human hepatitis B
virus mutations in the polymerase region. Hepatology 2001; 33(3): 751–757.
8. Niesters HG, de Man RA, Pas SD, Fries E, Osterhaus AD. Identification of a new variant in the
YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy.
J Med Microbiol 2002; 51(8): 695– 699.
9. Niesters HG, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus AD. Identification
of more than one muta tion in the hepatitis B virus polymerase gene arising during prolonged
lamivudine treatment. J Infect Dis 1998; 177(5): 1382–1385.
10. Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the
DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir,
L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000; 7(2): 161–165.
11. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and
lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348(2): 177–178.
12. Bruno R, Sacchi P, Zocchetti C, Ciappina V, Puoti M, Filice G. Rapid hepatitis B virus-DNA
decay in co-infected HIV-hepatitis B virus ‘e-minus’ patients with YMDD mutations after 4
weeks of tenofovir therapy. AIDS 2003; 17(5): 783– 784.
13. Nelson M, Portsmouth S, Stebbing J et al. An open-label study of tenofovir in HIV-1 and
hepatitis B virus co-infected individuals. AIDS 2003; 17(1): F7–F10.
14. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir
on hepatitis B virus repli cation in HIV-co-infected patients failing or partially responding to
lamivudine. AIDS 2002; 16(17): 2352–2354.